Genetic Predictors of Mortality in Patients with Multiple Myeloma

This article was originally published here

Appl Clin Genet. 2021 Apr 29;14:241-254. doi: 10.2147/TACG.S262866. eCollection 2021.


Multiple myeloma (MM) is a heterogeneous disease featured by clonal plasma cell proliferation and genomic instability. The advent of next-generation sequencing allowed unraveling the complex genomic landscape of the disease. Several recurrent genomic aberrations including immunoglobulin genes translocations, copy number abnormalities, complex chromosomal events, transcriptomic and epigenomic deregulation, and mutations define various molecular subgroups with distinct outcomes. In this review, we describe the recurrent genomic events identified in MM impacting patients’ outcome and survival. These genomic aberrations constitute new markers that could be incorporated into a prognostication model to eventually guide therapy at every stage of the disease.

PMID:33953598 | PMC:PMC8092627 | DOI:10.2147/TACG.S262866